European Psychiatry

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry

This retrospective registry study (n=176) of adults with treatment-resistant depression (TRD) at a Vienna outpatient clinic found that supervised intranasal esketamine induction was associated with a marked drop in clinician-rated depressive symptoms, with 27.2% reaching remission and 57.4% responding by the end of induction. Suicidal ideation fell significantly and tolerability was acceptable, with adverse events in 34.7% and few discontinuations.

Published

June 23, 2026

Journal

European Psychiatry

Authors

Preiss, M., Popper, V., Faber, L. H. C., Baumgartner, T., Baberis-Martinez, P. M., Winkler-Pjrek, E., Gryglewski, G., Bartova, L., Kasper, S., Rujescu-Balcu, D., Pezawas, L.

Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRD

This analysis of the randomised, open-label Phase IIIb ESCAPE-TRD study (n=676) compared esketamine nasal spray with extended-release quetiapine in treatment-resistant depression, tracking response to Week 32. Most esketamine-treated patients improved continuously, with early response linked to better long-term outcomes, and symptom resolution was greater and earlier than with quetiapine across most rated symptoms.

Published

June 16, 2026

Journal

European Psychiatry

Authors

Young, A., Bartova, L., Cardoner, N., Demyttenaere, K., Fagiolini, A., Godinov, Y., Golib Dzib, J., von Holt, C., McIntyre, R., Oliveira-Maia, A., Rive, B., Gorwood, P.

Magnitude of Response in Treatment and Control Groups within Psychedelic Trials for Psychiatric Disorders: A Meta-Analysis

Published

February 18, 2026

Journal

European Psychiatry

Authors

Meshkat, S., Lin, Q., Sousa-Ho, R., Demchenko, I., Zeifman, R. J., Fang, H., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A., Monson, C. M., Vermetten, E., Jetly, R., Lou, W., Husain, M. I., Burke, M. J., Bhat, V.

Effects of Psychedelic Microdosing versus Conventional ADHD Medication Use on Emotion Regulation, Empathy, and ADHD Symptoms in Adults with severe ADHD symptoms: A Naturalistic Prospective Comparison Study

Two naturalistic prospective studies in adults with severe ADHD symptoms found that psychedelic microdosing was associated with improved emotion regulation and a reduction in ADHD symptom severity over four weeks, with a persistent benefit on expressive suppression when compared with controls and conventional medication. There was no robust evidence that microdosing improved empathy.

Published

February 14, 2024

Journal

European Psychiatry

Authors

Haijen, E. C. H. M., Hurks, P. P. M., Kuypers, K. P. C.

Subjective effects of MDMA ('Ecstasy') on human sexual function

The study found that both the Arabic General Health Questionnaire (AGHQ) and the SRQ‑20 are valid screens for ICD‑10 psychiatric disorders in an Arab community in Al Ain (AGHQ: sensitivity 86%, specificity 85%, AUC 0.93; SRQ‑20: sensitivity 83%, specificity 83%, AUC 0.90), with the AGHQ performing significantly better overall, especially in males and those under 30. The abstract appears unrelated to the paper’s title on MDMA and sexual function.

Published

April 16, 2020

Journal

European Psychiatry

Authors

Zemishlany, Z., Aizenberg, D., Weizman, A.